COVID-19 trials registries data warehouse

http://en.irct.ir/trial/48048

Dr. Haleh Hamedifar

cinnagen@cinnagen.com

2020-05-16

Completed

RCT

Randomized

Parallel

Blind label

single-center

Treatment

Patients who have Covid-19 based on the CT-scan or RT-PCR findings Hospitalized patients Willingness to participate in the study for trial period and signing the informed consent form Age between 20-65

Pregnancy Breastfeeding Use of ARB/ACEi History of hypotension have no consent to participate in the study Allergic sensitivity to the interferon products Not availability of phone number or it is possible to be transferred to other hospitals Having the CKD or patients who need dialysis at the begining of the study Having any disease or condition that based on the physician judgment cannot participate in the study Participation in any other trials of Covid-19

2

CinnaGen company

20

100

Iran

Mild/moderate disease at enrollment

2: Mild/moderate disease at enrollment

50

The primary outcome was the evaluation of 50% reduction of viral load or negative results of virus before day 7

Phase 3

[{"arm_notes": "", "treatment_id": 671, "treatment_name": "Interferon beta 1a", "treatment_type": "Interferons", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]